<DOC>
	<DOCNO>NCT00007683</DOCNO>
	<brief_summary>Whether patient chronic heart failure ( CHF ) anticoagulated one old unresolved question cardiovascular therapeutic . Some authority recommend anticoagulation CHF patient sinus rhythm , others recommend anticoagulation patient primary cardiomyopathy , still others consider appropriate patient coronary artery disease ( CAD ) . This absence consensus reflect lack evidence area different outlooks objective therapy ( e.g. , prevention arterial embolus reduction vascular event ) .</brief_summary>
	<brief_title>Warfarin Antiplatelet Therapy Chronic Heart Failure</brief_title>
	<detailed_description>Primary Hypothesis : The hypothesis test whether aspirin , warfarin , clopidogrel equally effective treatment patient symptomatic CHF reduce ejection fraction . Secondary Hypothesis : If one therapy prove superior regard outcome , cost benefit ? Can subsets patient identify benefit specific approach antithrombotic therapy ? Intervention : The three treatment regimen : 1 . Open-label Warfarin titrate INR 2.5-3.0 ; 2 . Double blind aspirin 162 mg daily ; 3 . Double blind clopidogrel 75 mg daily . Primary Outcomes : Any death ( cause ) , non-fatal stroke , non-fatal MI . Study Abstract : Whether patient chronic heart failure ( CHF ) anticoagulated one old unresolved question cardiovascular therapeutic . Some authority recommend anticoagulation CHF patient sinus rhythm , others recommend anticoagulation patient primary cardiomyopathy , still others consider appropriate patient coronary artery disease ( CAD ) . This absence consensus reflect lack evidence area different outlooks objective therapy ( e.g. , prevention arterial embolus reduction vascular event ) . The original target sample size 4,500 3 year enrollment period 2 year follow-up . This sample size yield 90 % power detect relative difference 20 % treatment group . The sample size later amend 1,500 30 month enrollment period 12 month follow-up . The reduced sample size yield 85 % detect treatment difference 30 % . This change become effective March 2002 . This clinical trial enrol 1,587 patient 142 medical center ; VA non-VA center U.S. , medical center United Kingdom Canada . Patients randomly equally allocated 3 treatment : warfarin ( administer open-label ) , aspirin clopidogrel ( latter two administered double-blind ) . The study conduct 3.5 year period , 2.5 year enrollment phase . Patients NYHA class II , III , IV leave ventricular ejection fraction less equal 35 % ACE inhibitor ( unless tolerate ) diuretic enter . The primary end point composite death cause , non-fatal MI , non-fatal stroke . All-cause mortality secondary end point . The WATCH design paper publish Journal Cardiac Failure . Preliminary result present meeting American College Cardiology New Orleans March 9 , 2004 . There significant difference treatment group primary endpoint . The paper final result prepare .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients NYHA class II , III , IV leave ventricular ejection fraction less equal 35 % , ACE inhibitor ( unless tolerate ) diuretic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>aspirin</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>embolic event</keyword>
	<keyword>Left ventricular ejection fraction less eq</keyword>
	<keyword>NYHA Class II , III IV CHF</keyword>
	<keyword>symptomatic CHF</keyword>
	<keyword>warfarin</keyword>
</DOC>